ANI Pharma reports record Q4 revenue $247M, EPS $1.18; reaffirms 2026 guidance

ANI PHARMACEUTICALS INC

2025-FY EPS reported $3.32 vs consensus $2.04 ▲ beat (+63.1%)

Q4 total net revenue $247.1M (+29.6% YoY); Rare Disease segment $131.3M (+50.8%), Cortrophin Gel $111.4M (+87.6%).
Q4 GAAP diluted EPS $1.18; adjusted diluted EPS $2.33. Full year revenue $883.4M (+43.8%).
Generics Q4 revenue $100.8M (+28.2%) driven by partnered launch and new products.
Reaffirms FY2026 guidance: total revenue $1.055-1.115B; Cortrophin Gel $540-575M; adjusted EBITDA $275-290M.
Cash and equivalents $285.6M; operating cash flow $185.2M in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.